Pulmonary Arterial Hypertension (PAH) Medicine Market Report

Global and Region Pulmonary Arterial Hypertension (PAH) Medicine Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：162
  • REPORT CODE：GMM902466
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Pulmonary Arterial Hypertension (PAH) Medicine market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Pulmonary Arterial Hypertension (PAH) Medicinemarket, defines the market attractiveness level of Pulmonary Arterial Hypertension (PAH) Medicine market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Pulmonary Arterial Hypertension (PAH) Medicine industry, describes the types of Pulmonary Arterial Hypertension (PAH) Medicine market, the applications of major players and the market size, and deeply analyzes the current situation of the global Pulmonary Arterial Hypertension (PAH) Medicine market and the development prospects and opportunities of Pulmonary Arterial Hypertension (PAH) Medicine industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) Medicine market in Chapter 13.

    By Player:

    • United Therapeutics Corporation

    • GlaxoSmithKline

    • Bayer HealthCare

    • Arena Pharmaceuticals

    • Pfizer

    • Actelion Pharmaceuticals

    • Gilead Sciences

    By Type:

    • Endothelin Receptor Antagonists (ERA)

    • Prostacyclin And Prostacyclin Analogs

    • Phosphodiesterase 5 (PDE-5)

    • Soluble Guanylate Cyclase (SGC) Stimulators

    By End-User:

    • Secondary Pulmonary Hypertension (SPH)

    • Primary Pulmonary Hypertension (PPH)

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Pulmonary Arterial Hypertension (PAH) Medicine Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Pulmonary Arterial Hypertension (PAH) Medicine Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Pulmonary Arterial Hypertension (PAH) Medicine Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Outlook to 2022

    • 7.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 7.2 United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 7.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 7.4 China Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 7.5 Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 7.6 India Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    • 7.7 South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption (2017-2022)

    8 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Outlook to 2028

    • 8.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 8.2 United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 8.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 8.4 China Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 8.5 Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 8.6 India Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    • 8.7 South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast (2022-2028)

    9 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook by Types and Applications to 2022

    • 9.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Endothelin Receptor Antagonists (ERA) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Prostacyclin And Prostacyclin Analogs Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Phosphodiesterase 5 (PDE-5) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption and Growth Rate (2017-2022)

    • 9.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Secondary Pulmonary Hypertension (SPH) Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Primary Pulmonary Hypertension (PPH) Consumption and Growth Rate (2017-2022)

    10 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook by Types and Applications to 2028

    • 10.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Endothelin Receptor Antagonists (ERA) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Prostacyclin And Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Phosphodiesterase 5 (PDE-5) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Secondary Pulmonary Hypertension (SPH) Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Primary Pulmonary Hypertension (PPH) Consumption Forecast and Growth Rate (2022-2028)

    11 Global Pulmonary Arterial Hypertension (PAH) Medicine Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Analysis

    • 14.1 United Therapeutics Corporation

      • 14.1.1 United Therapeutics Corporation Company Details

      • 14.1.2 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • 14.2 GlaxoSmithKline

      • 14.2.1 GlaxoSmithKline Company Details

      • 14.2.2 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • 14.3 Bayer HealthCare

      • 14.3.1 Bayer HealthCare Company Details

      • 14.3.2 Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • 14.4 Arena Pharmaceuticals

      • 14.4.1 Arena Pharmaceuticals Company Details

      • 14.4.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • 14.5 Pfizer

      • 14.5.1 Pfizer Company Details

      • 14.5.2 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • 14.6 Actelion Pharmaceuticals

      • 14.6.1 Actelion Pharmaceuticals Company Details

      • 14.6.2 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • 14.7 Gilead Sciences

      • 14.7.1 Gilead Sciences Company Details

      • 14.7.2 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Pulmonary Arterial Hypertension (PAH) Medicine

    • Figure Pulmonary Arterial Hypertension (PAH) Medicine Picture

    • Table Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption by Country (2017-2022)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure China Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure India Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption and Growth Rate (2017-2022)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast by Country (2022-2028)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Medicine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Endothelin Receptor Antagonists (ERA) Consumption and Growth Rate (2017-2022)

    • Figure Global Prostacyclin And Prostacyclin Analogs Consumption and Growth Rate (2017-2022)

    • Figure Global Phosphodiesterase 5 (PDE-5) Consumption and Growth Rate (2017-2022)

    • Figure Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption and Growth Rate (2017-2022)

    • Figure Global Secondary Pulmonary Hypertension (SPH) Consumption and Growth Rate (2017-2022)

    • Figure Global Primary Pulmonary Hypertension (PPH) Consumption and Growth Rate (2017-2022)

    • Figure Global Endothelin Receptor Antagonists (ERA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prostacyclin And Prostacyclin Analogs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Phosphodiesterase 5 (PDE-5) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Soluble Guanylate Cyclase (SGC) Stimulators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Secondary Pulmonary Hypertension (SPH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Primary Pulmonary Hypertension (PPH) Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Pulmonary Arterial Hypertension (PAH) Medicine Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Pulmonary Arterial Hypertension (PAH) Medicine Export by Region (Top 5 Countries) (2017-2028)

    • Table United Therapeutics Corporation (Foundation Year, Company Profile and etc.)

    • Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • Table Bayer HealthCare (Foundation Year, Company Profile and etc.)

    • Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer HealthCare Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • Table Arena Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • Table Actelion Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product and Service

    • Table Gilead Sciences (Foundation Year, Company Profile and etc.)

    • Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US